FORT WORTH, TX / ACCESSWIRE / December 11, 2017 / Wound Management Technologies, Inc. (OTCQB: WNDM) today announced the first sale of its FDA-cleared HemaQuell™ Resorbable Bone Hemostat. Wound Management Technologies acquired a multi-faceted bone hemostasis and bone void filler patent in 2009 that led to the development of this new product. HemaQuell Hemostat is a new kind of water-soluble bone hemostat that controls bleeding from bone surfaces on application. It is delivered in a unique applicator that allows surgeons to directly apply the product on bleeding bone surfaces.

"We are extremely pleased to announce the first sale of HemaQuell Hemostat. We believe it is an ideal product to support our growing sales efforts in the acute surgical market, along with our CellerateRX® Surgical Activated Collagen® Adjuvant," commented J. Michael Carmena, Chief Financial Officer of Wound Management Technologies.

"HemaQuell Hemostat is perfect for a wide variety of surgical cases including orthopedic, cranial, cardiothoracic, and spinal procedures," noted Robert Mart, Vice-President of Marketing for Wound Management Technologies. "It stops bleeding as soon as it is applied to cut or damaged bone surfaces and is completely resorbed in 2 - 7 days. Studies have shown that it does not delay bone fusion or healing."

About Wound Management Technologies

With its number one goal of improving patient outcomes, Wound Management Technologies, develops, markets and distributes biotechnology products to physicians, hospitals, and clinics. It has a strong history of developing long-term, strategic partnerships with a focus on products that fuse nature with science. Its primary products are in the $11 billion U.S. consumable medical device market and in the $1.5 billion biomaterials market. Wound Management Technologies sells and distributes the patent-protected and FDA-cleared CellerateRX® Surgical Activated Collagen® Adjuvant and its new HemaQuell™ Resorbable Bone Hemostat.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Investor Relations
800-205-7719
ir@wmgtech.com

SOURCE: Wound Management Technologies, Inc.